Current therapeutic options for the treatment of Graves’ hyperthyroidism that are discussed below include those directly targeting the B cells or their associated interactors and cytokines, or alternatively, specific TSHR modulation by the use of small molecule antagonists, antagonistic TSHR monoclonal antibodies, or “tolerogenic” TSHR peptides (Fig. 1). Here, TSHR is linked to Graves disease.